Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Transl Psychiatry ; 6(11): e953, 2016 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-27845775

RESUMEN

The corticotropin releasing factor (CRF) exerts its effects by acting on its receptors and on the binding protein (CRFBP), and has been implicated in alcohol use disorder (AUD). Therefore, identification of the exact contribution of each protein that mediates CRF effects is necessary to design effective therapeutic strategies for AUD. A series of in vitro/in vivo experiments across different species were performed to define the biological discrete role of CRFBP in AUD. First, to establish the CRFBP role in receptor signaling, we developed a novel chimeric cell-based assay and showed that CFRBP full length can stably be expressed on the plasma membrane. We discovered that only CRFBP(10 kD) fragment is able to potentiate CRF-intracellular Ca2+ release. We provide evidence that CRHBP gene loss increased ethanol consumption in mice. Then, we demonstrate that selective reduction of CRHBP expression in the center nucleus of the amygdala (CeA) decreases ethanol consumption in ethanol-dependent rats. CRFBP amygdalar downregulation, however, does not attenuate yohimbine-induced ethanol self-administration. This effect was associated with decreased hemodynamic brain activity in the CRFBP-downregulated CeA and increased hemodynamic activity in the caudate putamen during yohimbine administration. Finally, in alcohol-dependent patients, genetic variants related to the CRFBP(10 kD) fragment were associated with greater risk for alcoholism and anxiety, while other genetic variants were associated with reduced risk for anxiety. Taken together, our data provide evidence that CRFBP may possess both inhibitory and excitatory roles and may represent a novel pharmacological target for the treatment of AUD.


Asunto(s)
Consumo de Bebidas Alcohólicas/genética , Alcoholismo/genética , Proteínas Portadoras/genética , Consumo de Bebidas Alcohólicas/fisiopatología , Alcoholismo/fisiopatología , Amígdala del Cerebelo/fisiopatología , Animales , Calcio/metabolismo , Membrana Celular/metabolismo , Regulación hacia Abajo/genética , Expresión Génica/genética , Humanos , Sistema Hipotálamo-Hipofisario/fisiopatología , Imagen por Resonancia Magnética , Masculino , Ratones , Ratones Endogámicos , Ratones Noqueados , Sistema Hipófiso-Suprarrenal/fisiopatología , Flujo Sanguíneo Regional/genética , Especificidad de la Especie , Adulto Joven
2.
Br J Pharmacol ; 171(14): 3420-31, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24628360

RESUMEN

BACKGROUND AND PURPOSE: Varenicline, a neuronal nicotinic acetylcholine receptor (nAChR) modulator, decreases ethanol consumption in rodents and humans. The proposed mechanism of action for varenicline to reduce ethanol consumption has been through modulation of dopamine (DA) release in the nucleus accumbens (NAc) via α4*-containing nAChRs in the ventral tegmental area (VTA). However, presynaptic nAChRs on dopaminergic terminals in the NAc have been shown to directly modulate dopaminergic signalling independently of neuronal activity from the VTA. In this study, we determined whether nAChRs in the NAc play a role in varenicline's effects on ethanol consumption. EXPERIMENTAL APPROACH: Rats were trained to consume ethanol using the intermittent-access two-bottle choice protocol for 10 weeks. Ethanol intake was measured after varenicline or vehicle was microinfused into the NAc (core, shell or core-shell border) or the VTA (anterior or posterior). The effect of varenicline treatment on DA release in the NAc was measured using both in vivo microdialysis and in vitro fast-scan cyclic voltammetry (FSCV). KEY RESULTS: Microinfusion of varenicline into the NAc core and core-shell border, but not into the NAc shell or VTA, reduced ethanol intake following long-term ethanol consumption. During microdialysis, a significant enhancement in accumbal DA release occurred following systemic administration of varenicline and FSCV showed that varenicline also altered the evoked release of DA in the NAc. CONCLUSION AND IMPLICATIONS: Following long-term ethanol consumption, varenicline in the NAc reduces ethanol intake, suggesting that presynaptic nAChRs in the NAc are important for mediating varenicline's effects on ethanol consumption.


Asunto(s)
Consumo de Bebidas Alcohólicas , Benzazepinas/farmacología , Dopamina/metabolismo , Etanol/antagonistas & inhibidores , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Quinoxalinas/farmacología , Receptores Nicotínicos/metabolismo , Consumo de Bebidas Alcohólicas/tratamiento farmacológico , Animales , Benzazepinas/administración & dosificación , Relación Dosis-Respuesta a Droga , Etanol/administración & dosificación , Masculino , Microinyecciones , Quinoxalinas/administración & dosificación , Ratas , Ratas Wistar , Relación Estructura-Actividad , Vareniclina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA